Erlotinib News and Research

RSS

Erlotinib is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib hydrochloride, OSI-774, and Tarceva.

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

ArQule to present tivantinib clinical trial data at ASCO 2014

ArQule, Inc. today announced that tivantinib will be included in seven presentations during the 2014 Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held from May 30, 2014 to June 3, 2014 in Chicago, Illinois.

31 May 2014

New database allows researchers to match old drugs for new diseases

There are thousands of drugs that silence many thousands of cancer-causing genetic abnormalities. Some of these drugs are in use now, but many of these drugs are sitting on shelves or could be used beyond the disease for which they were originally approved.

23 May 2014

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Disease progression-free survival is similar for patients with non-small-cell lung cancer and epidermal growth factor receptor mutations whether they receive erlotinib or gefitinib, show the results of a South Korean study.

21 May 2014

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex in combination with erlotinib (Tarceva) for late-stage lung cancer patients.

21 May 2014

Pemetrexed plus erlotinib shows benefits in NSCLC

Pemetrexed used in combination with erlotinib may have clinical advantage over single-agent pemetrexed when used as a second-line treatment in patients with non-squamous non-small-cell lung cancer, researchers report.

20 May 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology, Inc. reported financial results for its first quarter ended March 31, 2014, and provided an update on the Company's clinical development programs for the rest of 2014.

9 May 2014

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Most drugs used to treat lung, breast and pancreatic cancers also promote drug-resistance and ultimately spur tumor growth. Researchers at the University of California, San Diego School of Medicine have discovered a molecule, or biomarker, called CD61 on the surface of drug-resistant tumors that appears responsible for inducing tumor metastasis by enhancing the stem cell-like properties of cancer cells.

21 Apr 2014

AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test.

10 Apr 2014

New era of lung cancer therapy close to dawning

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.

27 Mar 2014

Cell-free DNA analysis allows noninvasive tumour genotype monitoring

Noninvasive tumour genotyping using cell-free plasma DNA analysis is feasible, say US researchers who believe the technique will aid patient diagnosis and monitoring.

24 Mar 2014

NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

Genomic fusion testing for echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase genes plus targeted first-line crizotinib is not a cost effective treatment strategy for patients with advanced non-squamous non-small-cell lung cancer, shows a Canadian analysis.

20 Mar 2014

Erlotinib has promising potential to improve treatment for cervical cancer

A new clinical study has found that erlotinib, a targeted antitumor agent, has promising potential to improve treatment for cervical cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the results indicate that larger trials are warranted to determine whether the drug should become part of standard therapy for women with the disease.

10 Mar 2014

Lung cancer patients with Del19 mutation benefit most from afatinib

Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

20 Feb 2014

IGF1R linked to mutation-negative lung cancer erlotinib resistance

Activation of the insulin-like growth factor 1 receptor plays a key role in acquired resistance to erlotinib in lung cancer with wild-type epidermal growth factor receptor, research suggests.

18 Feb 2014

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib should be given as a first-line treatment for Asian patients with advanced, epidermal growth factor receptor mutation-positive, non-small-cell lung cancer, researchers recommend.

17 Feb 2014

Everolimus fails to boost advanced NSCLC response

Phase II trial findings have ruled out a combination of erlotinib and everolimus for advanced non-small-cell lung cancer patients with progression after chemotherapy.

28 Jan 2014

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Pfizer Inc. today announced top-line results from two randomized Phase 3 studies of the irreversible pan-HER kinase inhibitor dacomitinib in patients with advanced non-small cell lung cancer.

28 Jan 2014

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as 'exciting' and a 'very promising therapy' in an editorial published in Neuro-Oncology, the leading journal of the Society of Neuro-Oncology.

21 Jan 2014

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months.

17 Dec 2013